Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Prostate Cancer

  Free Subscription


2 Anticancer Res
4 BJU Int
2 BMC Cancer
1 Br J Cancer
1 Br J Radiol
2 Cancer
2 Cancer Lett
2 Int J Radiat Oncol Biol Phys
1 J Magn Reson Imaging
3 J Nucl Med
3 J Urol
1 Lancet Oncol
2 PLoS One
2 Prostate
1 Ther Adv Urol
3 Urology

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Anticancer Res

  1. HOLM I, Hernroth B, Rosander A, Tassidis H, et al
    Manganese as a Possible Anticancer Enhancer in Docetaxel Treatment of Prostate Cancer Cells.
    Anticancer Res. 2024;44:953-962.
    PubMed         Abstract available

  2. YAMAMICHI G, Kato T, Watabe T, Hatano K, et al
    Current Status of Prostate-specific Membrane Antigen-targeted Alpha Radioligand Therapy in Prostate Cancer.
    Anticancer Res. 2024;44:879-888.
    PubMed         Abstract available

    BJU Int

  3. LEMANSKA A, Andrews C, Fisher L, Bacon S, et al
    During the COVID-19 pandemic 20 000 prostate cancer diagnoses were missed in England.
    BJU Int. 2024 Feb 27. doi: 10.1111/bju.16305.
    PubMed         Abstract available

  4. GEBOERS B, Scheltema MJV, Emmett L, Stricker PD, et al
    Reply to 'Re: Prostate-specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy'.
    BJU Int. 2024 Feb 28. doi: 10.1111/bju.16308.

  5. ROBERTS MJ, Conduit C, Davis ID, Effeney RM, et al
    The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy.
    BJU Int. 2024;133 Suppl 3:39-47.
    PubMed         Abstract available

  6. PTASZNIK G, Kelly BD, Murphy D, Lawrentschuk N, et al
    How prostate-specific membrane antigen positron emission tomography is refining risk calculators in the primary prostate diagnostic pathway.
    BJU Int. 2024;133 Suppl 3:13-14.

    BMC Cancer

  7. HUANG H, Liu Y, Wen Z, Chen C, et al
    Gut microbiota in patients with prostate cancer: a systematic review and meta-analysis.
    BMC Cancer. 2024;24:261.
    PubMed         Abstract available

  8. CHEN J, Yu F, He G, Hao W, et al
    A nomogram based on peripheral lymphocyte for predicting 8-year survival in patients with prostate cancer: a single-center study using LASSO-cox regression.
    BMC Cancer. 2024;24:254.
    PubMed         Abstract available

    Br J Cancer

  9. EBERLEIN C, Williamson SC, Hopcroft L, Ros S, et al
    Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer.
    Br J Cancer. 2024 Feb 23. doi: 10.1038/s41416-024-02614.
    PubMed         Abstract available

    Br J Radiol

  10. MCDAID L, Clough A, Benson KR, Nelder C, et al
    Geometric distortion caused by metallic femoral head prosthesis in prostate cancer imaging on an MR linac: in-vivo measurements of spatial deformation.
    Br J Radiol. 2024 Feb 24:tqae044. doi: 10.1093.
    PubMed         Abstract available


  11. WALBURN T, Chen MH, Loffredo M, McMahon E, et al
    Secondary analysis of late major gastrointestinal and genitourinary toxicities in unfavorable-risk prostate cancer patients receiving docetaxel: Insights from a randomized trial.
    Cancer. 2024 Mar 1. doi: 10.1002/cncr.35274.
    PubMed         Abstract available

  12. FARAJ KS, Kaufman SR, Oerline M, Herrel LA, et al
    The 340B Program and oral specialty drugs for advanced prostate cancer.
    Cancer. 2024 Feb 23. doi: 10.1002/cncr.35262.
    PubMed         Abstract available

    Cancer Lett

  13. YIN W, Chen G, Li Y, Li R, et al
    Identification of a 9-gene signature to enhance biochemical recurrence prediction in primary prostate cancer: A benchmarking study using ten machine learning methods and twelve patient cohorts.
    Cancer Lett. 2024 Feb 21:216739. doi: 10.1016/j.canlet.2024.216739.
    PubMed         Abstract available

  14. WEI Z, Zhang C, Song Y, Han D, et al
    CircUBE3A(2,3,4,5) promotes adenylate-uridylate-rich binding factor 1 nuclear translocation to suppress prostate cancer metastasis.
    Cancer Lett. 2024 Feb 27:216743. doi: 10.1016/j.canlet.2024.216743.
    PubMed         Abstract available

    Int J Radiat Oncol Biol Phys

  15. NEILSEN BK, Ma TM, Akingbemi WO, Neylon J, et al
    Impact of Interfractional Bladder and Trigone Displacement and Deformation on Radiation Exposure and Subsequent Acute Genitourinary Toxicity: A Post Hoc Analysis of Patients Treated with Magnetic Resonance Imaging-Guided Prostate Stereotactic Body Rad
    Int J Radiat Oncol Biol Phys. 2024;118:986-997.
    PubMed         Abstract available

  16. BESUGLOW J, Tessonnier T, Mein S, Eichkorn T, et al
    Understanding RBE and clinical outcome of prostate cancer therapy using particle irradiation: analysis of tumor control probability with mMKM.
    Int J Radiat Oncol Biol Phys. 2024 Feb 27:S0360-3016(24)00331.
    PubMed         Abstract available

    J Magn Reson Imaging

    Editorial for "Development and Validation of Interpretable Machine Learning Models for Clinically Significant Prostate Cancer Diagnosis in Patients With Lesions of PI-RADS v2.1 Score >/=3".
    J Magn Reson Imaging. 2024 Feb 29. doi: 10.1002/jmri.29277.

    J Nucl Med

  18. BOSCH D, van der Velden KJM, Oving IM, Wyndaele DNJ, et al
    The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of (223)Ra Therapy in Metastatic Castration-Resistant Prostate Cancer Patients.
    J Nucl Med. 2024 Feb 29:jnumed.123.266654. doi: 10.2967/jnumed.123.266654.
    PubMed         Abstract available

  19. GRIFFITHS MR, Pattison DA, Latter M, Kuan K, et al
    First-in-Human (212)Pb-PSMA-Targeted alpha-Therapy SPECT/CT Imaging in a Patient with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2024 Feb 29:jnumed.123.267189. doi: 10.2967/jnumed.123.267189.

  20. EL FAKIRI M, Ayada N, Muller M, Hvass L, et al
    Development and Preclinical Evaluation of [(211)At]PSAt-3-Ga: An Inhibitor for Targeted alpha-Therapy of Prostate Cancer.
    J Nucl Med. 2024 Feb 29:jnumed.123.267043. doi: 10.2967/jnumed.123.267043.
    PubMed         Abstract available

    J Urol

  21. MORGAN TM, Boorjian SA, Buyyounouski MK, Chapin BF, et al
    Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy.
    J Urol. 2024 Feb 14:101097JU0000000000003891. doi: 10.1097/JU.0000000000003891.
    PubMed         Abstract available

  22. MORGAN TM, Boorjian SA, Buyyounouski MK, Chapin BF, et al
    Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions.
    J Urol. 2024 Feb 14:101097JU0000000000003890. doi: 10.1097/JU.0000000000003890.
    PubMed         Abstract available

  23. MORGAN TM, Boorjian SA, Buyyounouski MK, Chapin BF, et al
    Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy.
    J Urol. 2024 Feb 19:101097JU0000000000003892. doi: 10.1097/JU.0000000000003892.
    PubMed         Abstract available

    Lancet Oncol

  24. DUAN H, Moradi F, Davidzon GA, Liang T, et al
    (68)Ga-RM2 PET-MRI versus MRI alone for evaluation of patients with biochemical recurrence of prostate cancer: a single-centre, single-arm, phase 2/3 imaging trial.
    Lancet Oncol. 2024 Feb 26:S1470-2045(24)00069.
    PubMed         Abstract available

    PLoS One

  25. ZAFEIROPOULOU K, Kalampounias G, Alexis S, Anastasopoulos D, et al
    Autophagy and oxidative stress modulation mediate Bortezomib resistance in prostate cancer.
    PLoS One. 2024;19:e0289904.
    PubMed         Abstract available

  26. Retraction: Somatostatin Derivative (smsDX) Targets Cellular Metabolism in Prostate Cancer Cells after Androgen Deprivation Therapy.
    PLoS One. 2024;19:e0299822.


  27. ALANAZI G, Alsubaie N, Nabi G, Gillingwater TH, et al
    Distribution of neurovascular structures within the prostate gland and their relationship to complications after radical prostatectomy.
    Prostate. 2024;84:491-501.
    PubMed         Abstract available

  28. KAMADA S, Sakamoto S, Kinoshita R, Zhao X, et al
    Testosterone bounce predicts favorable prognoses for prostate cancer patients treated with degarelix.
    Prostate. 2024 Feb 27. doi: 10.1002/pros.24679.
    PubMed         Abstract available

    Ther Adv Urol

  29. COQUAN E, Penel N, Lequesne J, Leman R, et al
    Carboplatin in metastatic castration-resistant prostate cancer patients with molecular alterations of the DNA damage repair pathway: the PRO-CARBO phase II trial.
    Ther Adv Urol. 2024;16:17562872241229876.
    PubMed         Abstract available


  30. MANDEL AL, Simhal RK, Shah YB, Wang KR, et al
    Racial disparities in diagnosis and treatment of depression Associated with androgen deprivation therapy for prostate cancer.
    Urology. 2024 Feb 21:S0090-4295(24)00094-3. doi: 10.1016/j.urology.2024.
    PubMed         Abstract available

  31. KHAN HM
    Editorial Commentary on Improving Racial Disparities in Prostate Cancer.
    Urology. 2024 Feb 21:S0090-4295(24)00095-5. doi: 10.1016/j.urology.2024.

  32. FROEHNER M, Gorner M, Merkle L, Kopka K, et al
    (18)Fluorine prostate-specific membrane antigen 1007 positron emission tomography for high-risk prostate cancer.
    Urology. 2024 Feb 27:S0090-4295(24)00131-6. doi: 10.1016/j.urology.2024.

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.